目的 探讨果糖二磷酸钠联合奥拉西坦治疗急性颅脑损伤的安全性与有效性。方法 选取2017年9月-2018年9月在漯河市中心医院就诊的急性颅脑损伤患者101例，随机将患者分成对照组（50例）和治疗组（51例）两组。对照组患者口服奥拉西坦胶囊，2粒/次，3次/d。治疗组患者在对照组基础上口服果糖二磷酸钠片，4片/次，3次/d。两组患者均连续治疗14 d。观察两组患者临床疗效，同时比较治疗前后两组患者格拉斯哥昏迷指数（GCS）评分、国立卫生研究院卒中量表（NIHSS）评分，及血清Tau蛋白、S100β蛋白和人低氧诱导因子-1α（HIF-1α）水平。结果 治疗后，对照组和治疗组临床总有效率分别为78.00%、94.12%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者GCS评分显著升高，NIHSS评分显著降低（P<0.05），且治疗组比对照组改善的更显著（P<0.05）。治疗后，两组患者血清Tau蛋白、S100β蛋白以及HIF-1α水平均显著降低（P<0.05），且治疗组患者明显低于对照组（P<0.05）。结论 果糖二磷酸钠联合奥拉西坦治疗急性颅脑损伤疗效显著、安全性高，且能够显著改善患者昏迷状态与神经功能，具有一定的临床推广应用价值。

Objective To investigate the safety and efficacy of fructose diphosphate sodium combined with oxiracetam in treatment of acute craniocerebral injury. Methods Patients (101 cases) with acute craniocerebral injury in Luohe Central Hospital from September 2017 to September 2018 were randomly divided into control (50 cases) and treatment (51 cases) groups. Patients in the control group were po administered with Oxiracetam Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Fructose Diphosphate Sodium Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the GCS and NIHSS scores, the serum levels of Tau protein, S100β protein and HIF-1α in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 78.00% and 94.12%, respectively, and there were differences between two groups (P<0.05). After treatment, the GCS scores in two groups were significantly increased, but the NIHSS scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of Tau protein, S100β protein and HIF-1α in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Fructose diphosphate sodium combined with oxiracetam is effective and safe in treatment of acute craniocerebral injury, can significantly improve the comatose state and nerve function, which has a certain clinical application value.

R971